Johnson & Johnson says IMAAVY sustained disease control in 2-year adolescent gMG study
J&J said Phase 2/3 adolescent extension data for IMAAVY showed disease control and functional improvement held up through two years, with some steroid reduction. The company also cited a retrospective survey of treatment switches and noted IMAAVY is an FcRn blocker with pediatric authorization in the U.S. and Europe fo